Your basket is currently empty!
ProImmune REVEAL® MHC-Peptide Binding Assays
Dr. Michael Mathis (Louisiana State University Health Sciences Center, USA)
“My work focuses on the development of adenovirus-based vectors for immunotherapy of breast cancer, using mouse models of the disease. ProImmune’s REVEAL® Rapid Epitope Discovery System has provided a cost-effective method for me to screen my proteins of interest for potentially immunogenic epitopes. I have been particularly impressed with the service that ProImmune offers, so much so that I’ve been telling my colleagues that they too should outsource more of their routine experiments to experts in order to free up their time. It really saves time and money when one take into account the effort needed to set up these assays in house and then wait for results. I will definitely be using the system again to obtain further data on the hits from the first round of screening.”
Dr. James Wells (Beth Israel Deaconess Medical Center, Boston, USA)
“I have dealt with ProImmune in the past and they have consistently proven to provide a high level of service. ProImmune’s REVEAL® service provided me with the option to test the in vitro binding properties of a selection of my most promising peptides quickly and efficiently, resulting in data I know I can trust.I have always found ProImmune to be very approachable and reliable, and their willingness to make contact with me directly over the telephone (following my initial e-mail request for further information) to discuss my requirements greatly helped me to fully understand the services offered and reassured me that my analysis would be conducted in a professional manner. The quotation process was simple, and my results were presented in several different formats to allow me to easily determine which peptides stood out for further investigation. Based on my results I have since gone on to order my custom peptide synthesis through ThinkPeptides, a branch of ProImmune.”
Dr. Ruben Varela-Calvino (University of Santiago de Compostela, Spain)
“Dr. Varela-Calvino has been researching a protein which acts as a target in autoimmune diabetes, and recently benefited from the ProImmune REVEAL® HLA-peptide binding assays. He and his team wanted to analyze the binding of some candidate peptides from his protein to HLA-DRB1*04:01, one of the major HLA types associated with autoimmune conditions. Dr Varela-Calvino has extensive experience performing HLA-peptide binding assays, and, recalling the length of the process, it wasn’t an experience he was keen to repeat: “Instead, I performed an internet search, and found ProImmune. I didn’t want to ask members of my lab to spend years optimizing an assay which ProImmune runs routinely – time in the lab is precious, particularly for Ph.D students”.ProImmune provided HLA-peptide binding assay results in a matter of weeks. His team were quickly able to move on to validating the binding assay data from ProImmune, and were delighted to find that the data they obtained from ELISpot experiments on patient samples correlated almost exactly with their results. As he moves towards collating his data for publication, Dr Varela-Calvino has nothing but praise for ProImmune. He told us “I’ve found the service from your team highly professional, the turnaround time for assays very impressive, and I would certainly work with ProImmune again in future”.
Dr. Birgit Schultes (Unither Pharmaceuticals, Massachusetts, USA)
“The report provided with the service and reagents was well organized and easy to understand. We are very happy with the data, the technical support and the on-time delivery of this technology. Several peptides and Pentamers were identified that will be useful for immune monitoring. Those Pentamers are currently confirmed with patient samples, pre- and post OvaRex® treatment”